Plasticell Announces Grant of Fundamental CombiCult™ Patents in USA and Japan
News Feb 14, 2012
Plasticell has announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan. Patents covering CombiCult™ have now been issued in Europe, USA, Japan, Australia and Singapore.
CombiCult™ breaks the major bottleneck in stem cell research and development programmes - the discovery of optimized stem cell differentiation protocols.
CombiCult™ also allows scientists to develop custom cell culture media (e.g. GMP compatible stem cell expansion media for cell therapy), create high value cell lines for toxicity testing in the pharmaceutical/cosmetic/nutrition industries, and to increase yield and/or decrease cost of bioprocess manufacturing.
“Plasticell’s proprietary technology breaks the major bottleneck in current stem cell research. Having followed CombiCult™’s development for almost a decade, I am delighted that the importance of this revolutionary technology is now being recognized through multiple industry awards and patents”, commented Sir Martin Evans FRS, a founding member of Plasticell’s Scientific Advisory Board and recipient of the Nobel prize for the isolation of embryonic stem cells.
Dennis Saw, CEO of Plasticell added, “Since 2002, Plasticell has continually innovated and expanded intellectual property coverage to secure its leading position in the stem cell space. Granted patents in the USA, Europe and Japan mean that the CombiCult™ process, which underlies many of our technologies, is now protected in all the major biotech markets which we operate in.”
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE